An inquiry was originally launched in autumn 2021 amid fears companies might decide to stop supplying medicines to Northern Ireland, and the committee wrote to the Government to set out its findings.
Today’s meeting is the second of the year after the committee held its first evidence meeting for this follow-up work on January 18th.
Currently, Northern Ireland’s medical supplies are delivered via the MHRA Authorized Route (NIMAR).
This route of supply was developed to ensure that people in Northern Ireland can continue to access prescription medicines in the event that clinical needs cannot be met. This includes the supply of medicines that are not approved in NI but are approved and licensed in the UK.
One of the main points of today’s meeting is to examine whether the Northern Ireland MHRA Authorized Route (NIMAR) is working effectively or not.
More broadly, today’s meeting is set to address the main issues that the Protocol is creating for the pharmaceutical industry in relation to the supply of medicines to Northern Ireland and how the industry has adapted or changed its operating model as a result of the Protocol.
The committee will also discuss any changes to cross-border healthcare as a result of the protocol.
Want a quick, expert briefing on the biggest news? Listen to our latest podcasts to find out what you need to know.